Резултати

eNauka >  Results >  Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Title: Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Authors : Howard, Jr James F.; ...; Perić, Stojan Z.  ; ...; (broj koautora 17)
Issue Date: 2024
Publication: Frontiers in neurology
ISSN: 1664-2295 Frontiers in Neurology Search Idenfier
Publisher: Lausanne : Frontiers Research Foundation
Type: Article
Collation: vol. 14 str. 1284444
DOI: 10.3389/fneur.2023.1284444
WoS-ID: 001156330800001
Scopus-ID: 2-s2.0-85184218524
PMID: 38318236
PMCID: PMC10842202
URI: https://enauka.gov.rs/handle/123456789/936653
URL: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1284444/full
Project: argenx
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
21M21

64
SCOPUSTM
36
PubMed CentralTM
60
WEB OF SCIENCETM
Алт метрика
Dimensions
Unpaywall

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.